



Notification pursuant to Article 5(1)(a) of Regulation (EU) No 596/2014 and Article 2(1) of Delegated Regulation (EU) No 2016/1052

8 December 2017

Fresenius Medical Care AG & Co. KGaA ("Fresenius Medical Care" or the "Company") will implement a share buy-back programme. The Company will make use of the authorization granted by the General Meeting on 12 Mai 2016 to acquire own shares pursuant to section 71 para. 1 no. 8 of the German Stock Corporation Act (*Aktiengesetz – AktG*). Under this share buy-back programme, up to a maximum of 660,000 ordinary shares (ISIN DE0005785802) will be repurchased at a total purchase price (excluding ancillary transaction costs) of up to 61 million Euro (approximately 72 million U.S. Dollar) in the period from 11 December 2017 until and including 22 December 2017. This corresponds to approximately 0.21 % of the share capital of Fresenius Medical Care. The own shares repurchased by the Company will be used for the sole purpose of reducing the registered share capital by cancellation of the repurchased own shares in order to neutralize the dilution from the Stock Option Plan 2011.

The shares will be repurchased on the stock exchange via the XETRA trading system. Pursuant to the conditions of the repurchase authorization granted by the Company's General Meeting on 12 Mai 2016, the price per share (excluding ancillary transaction costs) paid by the Company must not exceed or fall short of the market price of the Company's shares determined by the opening auction on the exchange trading day in the XETRA trading system by more than 10%.

The share buy-back will be made in accordance with the safe harbour provisions pursuant to Article 5 of Regulation No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) in conjunction with the provisions of the Commission Delegated Regulation 2016/1052 of 8 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to share buy-back programmes and stabilisation measures ("Delegated Regulation"). The share buy-back programme will be led by a credit institution on behalf and for the account of the Company, and such credit institution will make its decisions on the time of the buy-back of shares of Fresenius Medical Care independent of and without being influenced by the Company. In particular, the credit institution has agreed vis-à-vis Fresenius Medical Care to comply with the conditions of the repurchase authorization granted by the Company's General Meeting on 12 Mai 2016 and the conditions for trading pursuant to Article 3 para. 2 and para. 3 of the Delegated Regulation when executing the share buy-back programme. Pursuant to Article 3 para. 2 of the Delegated Regulation, shares may not be purchased under the share buy-back programme at a price higher than the higher of the price of the last independent trade and the highest current independent purchase bid on the trading venue where the purchase is carried out; at the same time, pursuant to Article 3 para. 3 of the Delegated Regulation, under the share buy-back programme, not more than 25% of the average daily volume of the shares on the trading venue on which the purchase is carried out may be purchased, whereby the average daily volume will be based on the average daily volume traded on the 20 trading days preceding the date of purchase.

The share buy-back programme may, to the extent necessary and permitted by law, be suspended and also be reinstated at any time.

Fresenius Medical Care will appropriately make available in detailed and aggregated form any information on any transactions in connection with the share buy-back programme no later than at the end of the seventh trading day after executing such transactions. In addition, Fresenius Medical Care will publish the notified transactions on its website at www.freseniusmedicalcare.com under section Investors and ensure that such information will be publicly accessible for at least five year from the day of the announcement.

Fresenius Medical Care AG & Co. KGaA

represented by Fresenius Medical Care Management AG

represented by its Management Board

Bad Homburg v.d.H., 8 December 2017